

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT SHARE REPURCHASE

This announcement is made by Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the announcement of the Company dated 6 October 2024 (the “**Announcement**”) in relation to the Company will conduct on-market share repurchase of up to HK\$500 million in aggregate based on market conditions and capital arrangement within twelve months from the date of the Announcement at the time and frequency determined by the Board from time to time. The board of directors of the Company (the “**Board**”) hereby announces that it intends to exercise its powers under the general mandate (the “**Repurchase Mandate**”) to repurchase shares of the Company granted by the shareholders of the Company at the annual general meeting held on 6 June 2025 to repurchase shares in the open market at appropriate timing.

The Board further announces that, on 17 June 2025, the Company repurchased, pursuant to the Repurchase Mandate, a total of 20,000,000 shares of the Company on market at an average price of HK\$1.0910 per share (the “**Share Repurchase**”). The aggregate purchase price paid (excluding commission and other expenses) for the Share Repurchase was approximately HK\$21,820,000. The repurchased shares represent approximately 0.2171% of the total number of issued shares (excluding treasury shares) of the Company as at the date of this announcement. The Company subsequently intended to hold the repurchased shares as treasury shares, and to use such treasury shares for subsequent sale or transfer.

The Board believes that the implementation of the Share Repurchase is in the interests of the Company and its shareholders as a whole. Sihuan Pharmaceutical has always been committed to achieving the strategic goal of becoming a leading medical aesthetics and biopharmaceutical enterprise in China. The Company has made several positive business progresses in its new businesses of medical aesthetics and innovative pharmaceuticals. The Company's carefully incubated medical aesthetics platform, Meiyuan Space, has evolved into a leading medical aesthetic company in China. It is a comprehensive integrated platform encompassing research, production and marketing, with a pipeline of more than 60 medical aesthetic products, covering the needs of the whole life cycle of beauty lovers. For the year ending 31 December 2024, revenue of the Group's medical aesthetic business segment was approximately RMB744.2 million, increasing approximately 65.4% year-on-year. In addition, the innovative drug R&D of the Group has entered a harvest period. From January 2024 to end of May 2025, the Group has obtained approval for the market launch of a total of 34 new medical aesthetic products and drugs, including a total of 9 medical aesthetic products including self-developed type III flagship product PCL filler (injectable polycaprolactone microsphere facial filler), PLLA filler (poly-L-lactic acid facial filler) and exclusively distributed type III flagship product dual-wave radiofrequency microneedle system Sylfirm X, as well as a total of 25 new drugs including Class 1 innovative drug Birociclib Tablets (Trade Name: Xuan Yue Ning) and Ganagliflozin Proline Tablets (Trade Name: Huiyoujing), and first domestic biosimilar Insulin Degludec and Insulin Aspart Injection (Trade Name: Huiyoujia), and Insulin Degludec Injection (Trade Name: Huiyouda). The Group expects that the simultaneous launch of such a large number of flagship new products will bring strong momentum to the Group's future revenue and profit growth. The Group holds great confidence in the Company's future development prospects.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of the Stock Exchange in 2010, Sihuan Pharmaceutical is an international medical aesthetics and biopharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic objective of "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavours to build itself into a leading medical aesthetics and biopharmaceutical company in China.

The Share Repurchase of the Company is subject to market conditions and will be made at the sole discretion of the Board. No guarantee is given as to the timing, amount or price of the shares to be repurchased. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 17 June 2025

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.